2026-04-13T01:16:44Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/127352025-05-03T03:20:39Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Müller, Volkmar author de Azambuja, Evandro author Gempt, Jens author Bachelot, Thomas author Curigliano, Giuseppe author Furtner, Julia author Saura Manich, Cristina author 2025-03-10T13:07:17Z 2025-03-10T13:07:17Z 2024 2025-01 Brain metastasis; Breast cancer; Prevention Metástasis cerebral; Cáncer de mama; Prevención Metàstasi cerebral; Càncer de mama; Prevenció Background Patients with HER2-positive breast cancer have a significant risk of developing brain metastases (BrM), which have detrimental effects on survival outcomes and quality of life. Although there are several systemic treatment options available that may delay the appearance of BrM and secondary progression of previously treated BrM, there are still substantial unmet needs for this patient population and primary prevention remains elusive. Methods A group of experts created consensus statements, through a modified Delphi process, to bridge the gap between current unmet needs, available evidence, and international guidelines. Results The steering committee reviewed all relevant literature and formed research questions to be answered by the subsequent consensus statements. In total, 61 contributors provided feedback on the consensus statements, with 34 statements reaching agreement out of the 55 statements that were voted on altogether. Statements with consensus aimed to define BrM primary and secondary prevention, screening procedures, assessment of symptoms, treatment efficacy, and preventing the occurrence and progression of BrM, while acknowledging the possibilities and limitations in daily clinical practice. Some statements did not reach agreement for a variety of reasons, mostly due to lack of evidence. Conclusions The consensus statements outlined in this publication provide a point of reference for daily clinical practice and can act as recommendations for clinical trial procedures and future guidelines. This work was funded by Seagen who had a role in organising the consensus meetings and outputs; however, they did not take part in the literature grading, consensus surveys or interpretation of results. http://hdl.handle.net/11351/12735 Decisió de grup Mama - Càncer Cervell - Càncer - Prevenció Metàstasi DISEASES::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Brain Neoplasms Other subheadings::Other subheadings::Other subheadings::/prevention & control DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema nervioso::neoplasias del sistema nervioso central::neoplasias cerebrales Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::psicología social::procesos de grupo::consenso ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer